SeaStar Medical To Showcase New Mechanistic Data Highlighting The Immunomodulatory Effect Of The Selective Cytopheretic Device In Acute Kidney Injury At ASN Kidney Week
SeaStar Medical To Showcase New Mechanistic Data Highlighting The Immunomodulatory Effect Of The Selective Cytopheretic Device In Acute Kidney Injury At ASN Kidney Week
SeaStar醫療將在ASN腎周展示新的機制數據，突出選擇性細胞療法設備在急性腎損傷中的免疫調節效應
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the presentation of new analyses of clinical data further supporting the immunomodulating effect of the Selective Cytopheretic Device (SCD) at the American Society of Nephrology (ASN) 2024 Kidney Week to be held October 24-27 in San Diego. Abstracts for the meeting are available here.
SeaStar Medical Holding Corporation（納斯達克: ICU）是一家商業化階段的醫療器械公司，開發專有解決方案，以減少高炎症對重要器官的影響，宣佈在美國腎臟病學會（ASN） 2024年腎臟研討會上展示新的臨床數據分析，進一步支持選擇性細胞淨化器（SCD）的免疫調節作用。該會議將於10月24日至27日在聖地亞哥舉行。會議摘要可在這裏獲取。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間